Literature DB >> 31944535

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.

Zhengyun Zou1, Qiuxiang Ou2, Yu Ren1, Qing Lv3, Lanqun Qin4, Lianjun Zhao1, Shu Su1, Xue Wu2, Hua Bao2, Ao Wang2, Dongqin Zhu5, Xiaonan Wang5, Yang W Shao2,6, Baorui Liu1.   

Abstract

The incidence of melanoma is rising globally including China. Comparing to Caucasians, the incidence of non-cutaneous melanomas is significantly higher in Chinese. Herein, we performed genomic profiling of 89 Chinese surgically resected primary melanomas, including acral (n = 54), cutaneous (n = 22), and mucosal (n = 13), by hybrid capture-based next-generation sequencing. We show that mucosal melanomas tended to harbor more pathogenic mutations than other types of melanoma, though the biological significance of this finding remains uncertain. Chromosomal arm-level alterations including 6q, 9p, and 10p/q loss were highly recurrent in all subtypes, but mucosal melanoma was significantly associated with increased genomic instability. Importantly, 7p gain significantly correlated with unfavorable clinical outcomes in non-cutaneous melanomas, representing an intriguing prognostic biomarker of those subtypes. Furthermore, focal amplification of 4q12 (KIT, KDR, and PDGFRα) and RAD51 deletion were more abundant in mucosal melanoma, while NOTCH2 amplification was enriched in acral melanoma. Additionally, cutaneous melanomas had higher mutation load than acral melanomas, while mucosal melanomas did not differ from other subtypes in mutation burden. Together, our data revealed important features of acral and mucosal melanomas in Chinese including distinctive driver mutation pattern and increased genomic instability. These findings highlight the possibilities of combination therapies in the clinical management of melanoma.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  combination therapy; concurrent pathogenic mutation; copy number variations; genomic instability; melanoma

Mesh:

Year:  2020        PMID: 31944535     DOI: 10.1111/pcmr.12865

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  6 in total

Review 1.  Evolving Treatment Approaches to Mucosal Melanoma.

Authors:  Shuai Zhang; Jiaran Zhang; Jun Guo; Lu Si; Xue Bai
Journal:  Curr Oncol Rep       Date:  2022-05-05       Impact factor: 5.945

2.  The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI).

Authors:  Lisa Elefanti; Carolina Zamuner; Paolo Del Fiore; Camilla Stagni; Stefania Pellegrini; Luigi Dall'Olmo; Alessio Fabozzi; Rebecca Senetta; Simone Ribero; Roberto Salmaso; Simone Mocellin; Franco Bassetto; Francesco Cavallin; Anna Lisa Tosi; Francesca Galuppini; Angelo Paolo Dei Tos; Chiara Menin; Rocco Cappellesso
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

3.  Systematic review and meta-analysis of genomic alterations in acral melanoma.

Authors:  Natasa Broit; Peter A Johansson; Chloe B Rodgers; Sebastian T Walpole; Nicholas K Hayward; Antonia L Pritchard
Journal:  Pigment Cell Melanoma Res       Date:  2022-03-07       Impact factor: 4.159

4.  Genetic alteration of Chinese patients with rectal mucosal melanoma.

Authors:  Huan Li; Lujing Yang; Yumei Lai; Xintong Wang; Xinyin Han; Siyao Liu; Dongliang Wang; Xiaojuan Li; Nana Hu; Yan Kong; Lu Si; Zhongwu Li
Journal:  BMC Cancer       Date:  2021-05-27       Impact factor: 4.430

Review 5.  More than just acral melanoma: the controversies of defining the disease.

Authors:  Sara S Bernardes; Ingrid Ferreira; David E Elder; Aretha B Nobre; Héctor Martínez-Said; David J Adams; Carla Daniela Robles-Espinoza; Patricia A Possik
Journal:  J Pathol Clin Res       Date:  2021-07-02

Review 6.  Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.

Authors:  Lili Mao; Zhonghui Qi; Li Zhang; Jun Guo; Lu Si
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.